NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.25 -0.04 (-3.10 %)
(As of 12/14/2018 02:17 PM ET)
Previous Close$1.29
Today's Range$1.25 - $1.32
52-Week Range$1.27 - $17.55
Volume329,540 shs
Average Volume375,265 shs
Market Capitalization$73.95 million
P/E Ratio-0.06
Dividend YieldN/A
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:MLNT
Previous Symbol


Debt-to-Equity Ratio0.46
Current Ratio1.34
Quick Ratio1.04


Trailing P/E Ratio-0.06
Forward P/E Ratio-0.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million
Price / Sales2.07
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.31 per share
Price / Book0.54


EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-202.31%
Return on Equity-68.68%
Return on Assets-32.84%


Outstanding Shares56,020,000
Market Cap$73.95 million

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.05) by $0.55. The biotechnology company earned $34.08 million during the quarter, compared to analyst estimates of $17.24 million. Melinta Therapeutics had a negative return on equity of 68.68% and a negative net margin of 202.31%. View Melinta Therapeutics' Earnings History.

When is Melinta Therapeutics' next earnings date?

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Melinta Therapeutics.

What price target have analysts set for MLNT?

6 Wall Street analysts have issued 1 year price objectives for Melinta Therapeutics' stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $12.30 in the next twelve months. This suggests a possible upside of 860.9% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.

What is the consensus analysts' recommendation for Melinta Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.

What are Wall Street analysts saying about Melinta Therapeutics stock?

Here are some recent quotes from research analysts about Melinta Therapeutics stock:
  • 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (11/2/2018)
  • 2. HC Wainwright analysts commented, "We note that Orbactiv is already approved by the EMA, whereas a MAA has yet to be filed for Minocin. While we await an 8-K filing for more details on the financial terms of this agreement, we point to three more near-term milestones for MLNT: (1) seven posters and one oral presentation later this week at Francisco (we are in attendance for the full duration); (2) sales and prescription trends from the 3Q18 results expected in early the pivotal Phase 3 data for Baxdela in community-acquired bacterial pneumonia (CABP) before year end. Affirm Buy." (10/2/2018)
  • 3. Cantor Fitzgerald analysts commented, "We expect sales of key drugs (such as to exceed consensus expectations. Therefore, upwards earnings revisions should drive MLNT’s stock higher, in our view. Valuation Summary We use a blend of P/E and DCF analysis to arrive at our $15 PT. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of P/E and DCF analysis to arrive at our $15 PT." (8/3/2018)

Has Melinta Therapeutics been receiving favorable news coverage?

News articles about MLNT stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Melinta Therapeutics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the near future.

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:
  • Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
  • Mr. John H. Johnson, Interim CEO & Director (Age 60)
  • Dr. Thomas A. Steitz Ph.D., Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen Ph.D., Co-Founder

Who are Melinta Therapeutics' major shareholders?

Melinta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.13%), BlackRock Inc. (4.33%), Stonepine Capital Management LLC (3.50%), Stonepine Capital Management LLC (3.50%), Vanguard Group Inc. (3.16%) and Vanguard Group Inc (3.16%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

Which institutional investors are selling Melinta Therapeutics stock?

MLNT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Virtus ETF Advisers LLC. View Insider Buying and Selling for Melinta Therapeutics.

Which institutional investors are buying Melinta Therapeutics stock?

MLNT stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Stonepine Capital Management LLC, BlackRock Inc., Sphera Funds Management LTD., JPMorgan Chase & Co., JPMorgan Chase & Co., First Manhattan Co. and Dimensional Fund Advisors LP. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $1.28.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $73.95 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

What is Melinta Therapeutics' official website?

The official website for Melinta Therapeutics is

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]

MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  496 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  851
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel